AR084886A1 - Proteinas de union a inhibidores de factores de coagulacion - Google Patents
Proteinas de union a inhibidores de factores de coagulacionInfo
- Publication number
- AR084886A1 AR084886A1 ARP120100166A ARP120100166A AR084886A1 AR 084886 A1 AR084886 A1 AR 084886A1 AR P120100166 A ARP120100166 A AR P120100166A AR P120100166 A ARP120100166 A AR P120100166A AR 084886 A1 AR084886 A1 AR 084886A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- presented
- cdr sequences
- antibody
- variable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Los anticuerpos y fragmentos funcionales de la presente y mimetizadores de anticuerpos pueden usarse para invertir específicamente el efecto farmacológico de un anticoagulante, por ejemplo, un inhibidor de FXa con fines terapéuticos (antídoto) y/o de diagnóstico. También proporciona secuencias de ácido nucleico que codifican las moléculas anteriores, vectores que contienen las mismas, composiciones farmacéuticas y equipos con instrucciones de uso.Reivindicación 1: Un anticuerpo aislado o un fragmento de unión a antígenos del mismo o mimetizadores de anticuerpos que neutralizan la actividad anticoagulante de un anticoagulante in vitro y/o in vivo. Reivindicación 6: Un anticuerpo aislado o fragmento de unión a antígenos del mismo o mimetizadores de anticuerpos de acuerdo con cualquiera de las reivindicaciones anteriores en las que el inhibidor de FXa es un compuesto que comprende un grupo de la fórmula (1), apixabán, betrixabán, razaxabán, edoxabán, otamixabán o YM-150 o en las que el inhibidor de trombina es dabigatrán. Reivindicación 9: El anticuerpo o un fragmento de unión a antígenos de acuerdo con cualquiera de las reivindicaciones anteriores que comprende: las secuencias de CDR de la cadena pesada variable de acuerdo a lo presentado por la SEC ID Nº 263 - 265 y las secuencias de CDR de la cadena liviana variable de acuerdo a lo presentado por la SEC ID Nº 266 - 268, o las secuencias de CDR de la cadena pesada variable de acuerdo a lo presentado por la SEC ID Nº 251 - 253 y las secuencias de CDR de la cadena liviana variable de acuerdo a lo presentado por la SEC ID Nº 254 - 256, o las secuencias de CDR de la cadena pesada variable de acuerdo a lo presentado por la SEC ID Nº 221 - 223 y las secuencias de CDR de la cadena liviana variable de acuerdo a lo presentado por la SEC ID Nº 224 - 226.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11151410 | 2011-01-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR084886A1 true AR084886A1 (es) | 2013-07-10 |
Family
ID=45491612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100166A AR084886A1 (es) | 2011-01-19 | 2012-01-18 | Proteinas de union a inhibidores de factores de coagulacion |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20140050743A1 (es) |
| EP (1) | EP2665751A1 (es) |
| JP (1) | JP2014506448A (es) |
| CN (1) | CN103619883A (es) |
| AR (1) | AR084886A1 (es) |
| CA (1) | CA2824885A1 (es) |
| WO (1) | WO2012098089A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109071637B (zh) * | 2016-03-23 | 2022-03-22 | 首尔大学校产学协力团 | 结合严重发热伴血小板减少综合征病毒的包膜糖蛋白的抗体及其用途 |
| GB201618432D0 (en) * | 2016-11-01 | 2016-12-14 | Matn Scient Ltd | Detection and treatment of demyelinating diseases |
| MX2019009106A (es) * | 2017-02-01 | 2019-09-10 | Novo Nordisk As | Anticuerpos procoagulantes. |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| AU5702298A (en) | 1996-12-03 | 1998-06-29 | Abgenix, Inc. | Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| WO2001064643A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
| US6669937B2 (en) * | 2000-04-20 | 2003-12-30 | The Board Of Trustees Of The University Of Arkansas | Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs |
| MXPA03011951A (es) | 2001-06-20 | 2004-03-26 | Daiichi Seiyaku Co | Derivados de diamina. |
| US7365205B2 (en) | 2001-06-20 | 2008-04-29 | Daiichi Sankyo Company, Limited | Diamine derivatives |
| BRPI0212726B8 (pt) | 2001-09-21 | 2021-05-25 | Bristol Myers Squibb Co | compostos contendo lactamas, e derivados dos mesmos, composição farmacêutica que os compreende e seus usos |
| DE102007028320A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028319A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| DK3078743T3 (da) * | 2007-09-28 | 2020-08-10 | Portola Pharm Inc | Antidoter til faktor xa-inhibitorer og fremgangsmåder til anvendelse af disse |
| MX2011004907A (es) * | 2008-11-14 | 2011-07-29 | Portola Pharm Inc | Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre. |
| AR079944A1 (es) * | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
-
2012
- 2012-01-17 EP EP12700348.1A patent/EP2665751A1/en not_active Withdrawn
- 2012-01-17 WO PCT/EP2012/050595 patent/WO2012098089A1/en active Application Filing
- 2012-01-17 CN CN201280014817.3A patent/CN103619883A/zh active Pending
- 2012-01-17 JP JP2013549784A patent/JP2014506448A/ja active Pending
- 2012-01-17 US US13/980,431 patent/US20140050743A1/en not_active Abandoned
- 2012-01-17 CA CA2824885A patent/CA2824885A1/en not_active Abandoned
- 2012-01-18 AR ARP120100166A patent/AR084886A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2824885A1 (en) | 2012-07-26 |
| US20140050743A1 (en) | 2014-02-20 |
| JP2014506448A (ja) | 2014-03-17 |
| WO2012098089A1 (en) | 2012-07-26 |
| EP2665751A1 (en) | 2013-11-27 |
| CN103619883A (zh) | 2014-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087567A1 (es) | Anticuerpos anti-tie2 y usos de los mismos | |
| CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
| AR127516A2 (es) | VARIANTES DE Fc Y MÉTODOS PARA SU PRODUCCIÓN | |
| AR122771A2 (es) | Anticuerpos para el tratamiento del cáncer, conjugado, composición farmacéutica, ácido nucleico y célula huésped | |
| UY33196A (es) | Antidotos de anticoagulantes | |
| EA201591091A1 (ru) | Антигенсвязывающие белки для bcma | |
| CL2019002056A1 (es) | Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650) | |
| AR092005A1 (es) | Anticuerpos anti-pcsk9 y uso de los mismos | |
| CY1119994T1 (el) | Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α | |
| CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| ECSP17005649A (es) | Anticuerpos anti-tau humanizados | |
| CO6260094A2 (es) | Anticuerpos novedosos anti-alpha5beta1 y usos de los mismos | |
| RU2012143793A (ru) | Биспецифические двухвалентные антитела анти-vegf/анти-ang-2 | |
| EA201490825A1 (ru) | Tdp-43-специфически связывающие молекулы | |
| EA201591113A1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение | |
| AR083747A1 (es) | Anticuerpos anti-il-23 | |
| EA201491569A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
| AR095432A1 (es) | Proteínas de unión a antígeno | |
| CY1118551T1 (el) | Μεθοδοι θεραπειας αυτοανοσων νοσων με ανταγωνιστες του dll4 | |
| BR112014011331A2 (pt) | anticorpos específicos para trop-2 e seus usos | |
| BR112015029953A2 (pt) | anticorpos anti-tweakr e seus usos | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| AR093584A1 (es) | Inmunoglobulinas heterodimericas | |
| AR077111A1 (es) | Proteinas biespecificas tetravalentes de union a antigeno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |